SPRB Stock Analysis: Buy, Sell, or Hold?
SPRB - Spruce Biosciences, Inc. Common Stock
$55.11
2.34 (4.43%)
▲
5d:
+5.25%
30d:
+11.29%
90d:
-20.26%
BUY
MODERATE Confidence
Analysis Updated: Jun 26, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When SPRB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SPRB shows positive signals but monitor for confirmation. Market pricing in 17.5% decline. Moderate conviction.
💡 BUY OPPORTUNITY: SPRB shows positive signals but monitor for confirmation. Market pricing in 17.5% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$137.33
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$85.27
35.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 19.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SPRB is currently trading at $55.11, which is considered extended relative to its 30-day fair value range of $48.73 to $52.82. From a valuation perspective, the stock is trading at a discount (Forward PE: 11.1) compared to its historical average (19.8). Remarkably, the market is currently pricing in an annual earnings decline of 17.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, SPRB is in a strong downtrend. The price is approaching resistance at $54.32. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.4% recently.
Market Sentiment: SPRB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $149.71 (+171.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SPRB is in a strong downtrend. The price is approaching resistance at $54.32. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.4% recently.
Market Sentiment: SPRB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $149.71 (+171.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$48.73 -
$52.82
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.4%)
- BULLISH: Trading 171.7% below Wall St target ($149.71)
Trading Range Analysis
30-Day Trading Range
$48.73 -
$52.82
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$46.70
Resistance Level
$54.32
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.13
Wall Street Target
$149.71
(+171.7%)
Revenue Growth (YoY)
-75.9%
Valuation Discount vs History
-17.5% cheaper
PE vs Historical
11.1 vs 19.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-17.5%
(market-implied from PE analysis)
1-Year Target
$49.60
(-10%)
2-Year Target
$44.64
(-19%)
3-Year Target
$40.18
(-27%)
3-Yr Target (if PE normalizes)
(PE: 11→20)
$71.45
(+30%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 11.1 to 19.8
Stabilization Target:
$98.01
(+77.8%)
PE Expansion Potential:
+77.8%
Share & Embed Analysis
Last updated: June 29, 2026 2:58 AM ET
Data refreshes hourly during market hours. Next update: 3:58 AM
Data refreshes hourly during market hours. Next update: 3:58 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SPRB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 65 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 56 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 58 HOLD |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 67 BUY |
|
MNMD
Mind Medicine Inc |
STRONG BUY
11 analysts |
$29 | 62 BUY |
